OncoMylo

OncoMylo is a Swiss-based biotechnology company focused on developing innovative cancer immunotherapies that target the myeloid cell compartment within the tumor microenvironment. A spin-off from the University of Zurich and University Hospital Zurich, the company leverages proprietary insights into myeloid biology to reprogram tumor-associated macrophages from immunosuppressive to immunostimulatory states. Their primary therapeutic approach involves high-affinity monoclonal antibodies designed to selectively bind and modulate key myeloid receptors, such as CD163. By targeting these cells, OncoMylo aims to overcome the limitations of current T-cell-focused therapies and provide new options for patients with resistant solid tumors and hematological malignancies. The company is currently advancing its lead programs through preclinical development while expanding its platform for broader myeloid modulation.